Welcome to our dedicated page for Dianthus Therapeutics SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dianthus Therapeutics, Inc. (DNTH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company listed on The Nasdaq Capital Market under the symbol DNTH, Dianthus uses SEC reports to communicate material events, financial results, and key agreements related to its development of therapies for severe autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results, positive top-line Phase 2 data for claseprubart (DNTH103) in generalized myasthenia gravis, and an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants. Other 8-K filings describe a license and collaboration agreement with Nanjing Leads Biolabs Co. Ltd. for DNTH212 (LBL-047), outlining the exclusive license outside Greater China, milestone and royalty structure, and joint governance for development and commercialization.
Through this page, users can review how Dianthus reports its cash position, research and development expenses, and other financial metrics in connection with clinical-stage operations. Filings also document regulatory and corporate milestones that affect the company’s pipeline of investigational agents, including claseprubart and DNTH212, both of which are described as not approved as therapies in any indication in any jurisdiction worldwide.
Stock Titan enhances access to these filings with AI-powered summaries that explain the main points of lengthy documents, helping readers quickly understand material agreements, capital raises, and clinical or financial updates. Investors and researchers can use this resource to follow DNTH’s official disclosures, track changes over time, and connect specific filings to press releases and clinical news about the company’s autoimmune-focused programs.
Dianthus Therapeutics, Inc. (DNTH) Form 144 notifies the SEC of a proposed sale of 20,000 shares of common stock acquired on 09/09/2025 via exercise of stock options from the issuer. The filer lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker, with an approximate aggregate market value of $636,000.00 and that the company has 32,188,345 shares outstanding. The notice indicates the shares were to be paid for in cash on the same acquisition date and that there were no reported sales by the seller in the prior three months. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Dianthus Therapeutics is offering shares of common stock and pre-funded warrants exercisable for common stock. Each pre-funded warrant has an exercise price of $0.001 per share and is exercisable any time after issuance subject to ownership limits (holders may elect limits up to 19.99% with prior notice). The company does not intend to list the pre-funded warrants, which may limit liquidity. The prospectus states the company will use net proceeds to advance preclinical and clinical development and for working capital. The public offering price per share and certain total dollar amounts are redacted in the provided text. The company’s common stock trades on Nasdaq under DNTH, with a last reported sale price of $26.50 on September 5, 2025. The prospectus warns new investors will incur immediate dilution (amounts redacted) and describes cashless exercise mechanics and transfer and tax considerations for U.S. and Non-U.S. holders.
Dianthus Therapeutics announced positive top-line results from its Phase 2 MaGic trial of claseprubart (DNTH103) in adults with acetylcholine receptor antibody positive generalized myasthenia gravis. The study evaluated both safety and efficacy of DNTH103 in this autoimmune neuromuscular disease population.
The company is hosting a conference call and webcast on September 8, 2025, at 8:00 a.m. Eastern Time to discuss the data. A detailed press release and an investor data presentation have been made available as exhibits and on the company’s website, providing more insight into the trial outcomes.
Venrock-related investors report a 1,000,000-share position in Dianthus Therapeutics (DNTH), representing 3.1% of the outstanding common stock. The disclosed holdings break down into 75,943 shares held by Venrock Healthcare Capital Partners III, 7,588 shares held by VHCP Co-Investment Holdings III, and 916,469 shares held by Venrock Healthcare Capital Partners EG. The reporting group states these shares were not acquired to influence or change control of the company. The percentage ownership is calculated using 32,159,982 shares outstanding as reported in the issuer's prior SEC filing.
Dianthus Therapeutics, Inc. Schedule 13G/A reports that Point72-related entities and Steven A. Cohen collectively have shared voting and dispositive power over 1,445,825 shares of Dianthus common stock, representing 4.5% of the class as of the close of business on June 30, 2025. The filing states the shares are held by an investment fund managed by Point72 Asset Management; Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management and Mr. Cohen controls both entities. Each reporting person reports 0 sole voting and 0 sole dispositive power, with all reported power listed as shared. The statement clarifies the filing should not be construed as admission of beneficial ownership for purposes of Section 13.
BCLS Fund III Investments, LP reported beneficial ownership in Dianthus Therapeutics (DNTH) totaling 2,482,250 shares as of June 30, 2025. That total comprises 1,481,917 outstanding shares and a pre-funded warrant exercisable into 1,000,333 shares, representing approximately 7.5% of the common stock based on 32,176,482 shares outstanding. The filing notes the pre-funded warrant cannot be exercised to the extent it would raise ownership above 9.99%, and the Reporting Person asserts the holdings are not intended to change or influence control of the issuer. The filing was signed by Ricky Sun on behalf of BCLS Fund III Investments, LP.
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of 3,200,000 shares of Dianthus Therapeutics common stock, representing 9.95% of the outstanding class. The stake is held by a Vestal Point fund and managed account for which Vestal Point acts as investment manager; Mr. Wilder is identified as the investment manager's Chief Investment Officer and Managing Partner and reports shared voting and dispositive power over the shares. The percent calculation is based on 32,159,982 shares outstanding as of the company report for the quarter ended March 31, 2025. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.